Design Therapeutics, Inc.

DSGN

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001807120

SEC filings (opens in a new tab)

No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding Design Therapeutics, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026 All holders in Q1 2026

13F holders of DSGN: Q1 2026 compared with Q2 2026
Measure	Q1 2026	Of which not filed for Q2 2026	Q2 2026	Change
Holders	125	1	136	+12
Shares	38.0M	423	43.3M	+5.32M (+14.0%)
Value	$404.1M	$4.50K	$626.4M	+$222.3M (+55.0%)

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (28)

Institutions that held Design Therapeutics, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to DSGN in Q2 2026
Institution	Shares	Value	% of portfolio
Frazier Life Sciences Management, L.P.	1,809,854	$26.2M	0.57%
Sofinnova Investments, Inc.	865,135	$12.5M	0.67%
Siren, L.L.C.	523,212	$7.57M	0.15%
Eversept Partners, LP	190,000	$2.75M	0.15%
KVP Capital Advisors, LP	185,000	$2.68M	1.96%
J. Goldman & Co LP	176,770	$2.56M	0.09%
Balyasny Asset Management LLC	111,103	$1.61M	0.00%
DAFNA Capital Management LLC	102,600	$1.48M	0.28%
SummitTX Capital, L.P.	80,663	$1.17M	0.03%
ExodusPoint Capital Management, LP	41,286	$597.4K	0.01%
Susquehanna Portfolio Strategies, LLC	33,375	$482.9K	0.01%
Oppenheimer & Co Inc	32,087	$464.3K	0.00%
Virtus Investment Advisers, Inc.	29,827	$431.6K	0.10%
Wellington Management Group LLP	19,400	$280.7K	0.00%
Creative Planning	15,844	$229.3K	0.00%
Susquehanna International Group, LLP	15,650	$226.5K	0.00%
Y-Intercept (Hong Kong) Ltd	12,910	$186.8K	0.00%
Susquehanna Fundamental Investments, LLC	12,553	$181.6K	0.00%
Gsa Capital Partners LLP	10,328	$149.0K	0.01%
State of Wyoming	2,566	$37.1K	0.00%
Allied Private Wealth LLC	880	$13.4K	0.01%
SRS Capital Advisors, Inc.	180	$2.61K	0.00%
Simplex Trading, LLC	172	$2.49K	0.00%
Versant Capital Management, Inc	86	$1.24K	0.00%
Silver Grove Financial Group, Inc.	58	$839	0.00%
Quarry LP	31	$449	0.00%
SBI Securities Co., Ltd.	10	$145	0.00%
SJS Investment Consulting Inc.	4	$58	0.00%

Sold out (16)

Institutions that held Design Therapeutics, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of DSGN in Q2 2026
Institution	Shares, Q1 2026	Value, Q1 2026
Ra Capital Management, L.P.	2,972,973	$31.6M
Kynam Capital Management, LP	784,606	$8.35M
Marshall Wace, LLP	151,008	$1.61M
Lynx1 Capital Management LP	119,516	$1.27M
Jane Street Group, LLC	103,902	$1.11M
EAM Investors, LLC	78,949	$840.0K
Velan Capital Investment Management LP	20,000	$212.8K
Engineers Gate Manager LP	16,090	$171.2K
Brevan Howard Capital Management LP	15,294	$162.7K
Dynamic Technology Lab Private Ltd	14,749	$156.9K
Mariner, LLC	13,066	$138.9K
Baader Bank INC	12,792	$136.1K
Mirabella Financial Services LLP	11,814	$125.7K
ADAR1 Capital Management, LLC	10,000	$106.4K
Root Financial Partners, LLC	38	$404
MAI Capital Management	8	$86

Not filed for Q2 2026 yet (1)

Institutions that held Design Therapeutics, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding DSGN in Q1 2026 that haven't filed for Q2 2026
Institution	Shares, Q1 2026	Value, Q1 2026
CWM, LLC	423	$4.50K